Trials / Conditions / EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

6 registered clinical trials studyying EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363	University of Washington	Phase 2
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Suspended	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag NCT04799275	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877	University of Washington	Phase 1
Active Not Recruiting	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lympho NCT03984448	National Cancer Institute (NCI)	Phase 2 / Phase 3
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2